These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. Schneider PM; Casson AG; Levin B; Garewal HS; Hoelscher AH; Becker K; Dittler HJ; Cleary KR; Troster M; Siewert JR; Roth JA J Thorac Cardiovasc Surg; 1996 Feb; 111(2):323-31; discussion 331-3. PubMed ID: 8583805 [TBL] [Abstract][Full Text] [Related]
4. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048 [TBL] [Abstract][Full Text] [Related]
5. Clinical implications of p53 gene mutation in the progression of Barrett's epithelium to invasive esophageal cancer. Casson AG; Manolopoulos B; Troster M; Kerkvliet N; O'Malley F; Inculet R; Finley R; Roth JA Am J Surg; 1994 Jan; 167(1):52-7. PubMed ID: 8311140 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Ramel S; Reid BJ; Sanchez CA; Blount PL; Levine DS; Neshat K; Haggitt RC; Dean PJ; Thor K; Rabinovitch PS Gastroenterology; 1992 Apr; 102(4 Pt 1):1220-8. PubMed ID: 1551529 [TBL] [Abstract][Full Text] [Related]
7. Potential application of p53 as an intermediate biomarker in Barrett's esophagus. Jones DR; Davidson AG; Summers CL; Murray GF; Quinlan DC Ann Thorac Surg; 1994 Mar; 57(3):598-603. PubMed ID: 8147627 [TBL] [Abstract][Full Text] [Related]
8. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Hamelin R; Fléjou JF; Muzeau F; Potet F; Laurent-Puig P; Fékété F; Thomas G Gastroenterology; 1994 Oct; 107(4):1012-8. PubMed ID: 7523212 [TBL] [Abstract][Full Text] [Related]
9. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53. Feith M; Stein HJ; Mueller J; Siewert JR Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371 [TBL] [Abstract][Full Text] [Related]
10. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report. Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596 [TBL] [Abstract][Full Text] [Related]
11. p53 in esophageal adenocarcinoma: a critical reassessment of mutation frequency and identification of 72Arg as the dominant allele. Chung SM; Kao J; Hyjek E; Chen YT Int J Oncol; 2007 Dec; 31(6):1351-5. PubMed ID: 17982662 [TBL] [Abstract][Full Text] [Related]
12. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus. Halm U; Tannapfel A; Breitung B; Breidert M; Wittekind CW; Mössner J Hepatogastroenterology; 2000; 47(34):962-6. PubMed ID: 11020858 [TBL] [Abstract][Full Text] [Related]
13. [Immunohistochemical expression of the p53 and Ki-67 proteins in Barrett's esophagus in Korea]. Kim CW; Lee BI; Kim BW; Kim JI; Park SH; Kim JK; Han SW; Jung IS; Sun HS; Lee AW; Lee KY Korean J Gastroenterol; 2005 Sep; 46(3):189-95. PubMed ID: 16179838 [TBL] [Abstract][Full Text] [Related]
14. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus. Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797 [TBL] [Abstract][Full Text] [Related]
15. TP53 mutations in malignant and premalignant Barrett's esophagus. Dolan K; Walker SJ; Gosney J; Field JK; Sutton R Dis Esophagus; 2003; 16(2):83-9. PubMed ID: 12823203 [TBL] [Abstract][Full Text] [Related]